Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Sudden Cardiac Death Risk in Newly Diagnosed Heart Failure: SCD-PROTECT
Author(s): Marat Fudim , David Duncker Added: 2 weeks ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19… View more

Electrophysiology & Arrhythmia

Heart Failure
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 1 week ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
HFSA 24: The EMBARK HFpEF Trial
Author(s): Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the… View more

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 3 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Treatment Landscape for Cardiac Amyloidosis with Dr Sarah Cuddy
Author(s): Added: 6 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly… View more

Heart Failure
CPET and Exercise Prescription for Cardiac Rehabilitation
Author(s): Kaoutar Kabbadj , Nora Taiek , Wiame El Hjouji , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Multimodality Imaging in Cardiac Amyloidosis with Dr Vasvi Singh
Author(s): Vasvi Singh Added: 6 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights… View more

Heart Failure

Imaging & Diagnostics
Transthyretin Cardiac Amyloidosis: A Right-atrial Variant
Author(s): Narra Lavanya , Abraham Oomman Added: 11 months ago

Imaging & Diagnostics

Heart Failure
Erratum: Rehabilitation, Reverse Remodeling, and Cardiac Recovery
Added: 9 months ago

Intervention
New Innovations to Address Sudden Cardiac Arrest
Author(s): Christine Shen , Sanjeev P Bhavnani , John D Rogers Added: 1 year ago

Electrophysiology & Arrhythmia